

Delphi-MD Brain Health Diagnosis at Any Point-of-Care - Iftach Dolev

Company name: QuantalX Neuroscience Ltd

Website: <https://quantalx.com/>

CEO: Iftach Dolev PhD

Category: - Biotech/Pharma or Medical Devices or Health IT/Digital

Sessions: - Unlocking a new era in brain health innovation - What can we do to make healthier aging a reality? Abstract: Delphi-MD Brain Health Diagnosis at Any Point of Care

Iftach Dolev PhD CEO and Co-Founder, QuantalX Neuroscience Ltd

o Executive Summary: As the world's population ages, the prevalence of neurological disorders and the need for preserving brain health are on the rise. Current available tools and methodologies to front-line physicians and neurologists in the clinical setting are limited. Delphi-MD is a first-in-class direct brain network visualization device, offering quantitative clinical measurements of neuronal physiology in a non-invasive, and safe manner.

o Core Technology: Delphi-MD combines high resolution, non-invasive, magnetic stimulation and brain monitoring. By magnetically probing specific neural networks the Delphi-MD device measures brain physiology in a direct, and objective manner providing, for the first time, an easy and accessible tool for the evaluation, monitoring, and diagnosis of brain network health in any point of care.

o Product Profile: Delphi-MD demonstrates significant diagnostic value in a wide range of diseases including MCI, Dementia, Alzheimer's disease, Lewy body disease, NPH, stroke, TBI and more. Delphi-MD was granted twice as a breakthrough designation medical device by the FDA, first, for early detection of risk for stroke and dementia and second, for diagnosis and prediction of treatment success of NPH.

o Business Strategy: Delphi-MD is currently used in leading medical centers in the US and in Israel. Providing maximal value for physicians, payors and of course, patients. The company is part of the new and prestigious Total Life Cycle Advisory Program (TAP) initiated by the FDA to ensure that patients have access to high-quality, safe, effective, and innovative medical devices. o What's Next? In the coming year the company will continue and establish the commercialization of Delphi-MD in the different target market of Israel, Europe and of course, the US. Introducing Delphi-MD into the brain health clinical workflow is the missing piece for the early and successful detection and monitoring of

brain health, providing an optimal and personalized neurological care management and treatment.